These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

533 related items for PubMed ID: 14730270

  • 21. Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection.
    Hussell T, Georgiou A, Sparer TE, Matthews S, Pala P, Openshaw PJ.
    J Immunol; 1998 Dec 01; 161(11):6215-22. PubMed ID: 9834108
    [Abstract] [Full Text] [Related]

  • 22. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
    Johnson TR, Parker RA, Johnson JE, Graham BS.
    J Immunol; 2003 Feb 15; 170(4):2037-45. PubMed ID: 12574374
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination.
    Helson R, Olszewska W, Singh M, Megede JZ, Melero JA, O'Hagan D, Openshaw PJ.
    Vaccine; 2008 Feb 06; 26(6):753-61. PubMed ID: 18191308
    [Abstract] [Full Text] [Related]

  • 25. The effect of IL-12 treatment on vaccine-enhanced illness during infection with respiratory syncytial virus.
    Openshaw PJ, Hussell T.
    Dev Biol Stand; 1998 Feb 06; 92():179-85. PubMed ID: 9554273
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation.
    Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A, Wilschut J.
    Vaccine; 2010 Aug 02; 28(34):5543-50. PubMed ID: 20600502
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection.
    Fischer JE, Johnson JE, Johnson TR, Graham BS.
    J Infect Dis; 2000 Oct 02; 182(4):1029-38. PubMed ID: 10979896
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine.
    Cyr SL, Jones T, Stoica-Popescu I, Burt D, Ward BJ.
    Vaccine; 2007 Apr 20; 25(16):3228-32. PubMed ID: 17374422
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.